Role of corticosteroids for fatigue in advanced incurable cancer: Is it a 'wonder drug' or 'deal with the devil'

Current Opinion in Supportive and Palliative Care

Volumn 8, Issue 4, 2014, Pages 346-351

  Yennurajalingam, Sriram ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Advanced cancer; Corticosteroid rotation; Corticosteroids; Myopathy; Palliative care

Indexed keywords

CORTICOSTEROID;

ANOREXIA; CHEMICALLY INDUCED; COMPLICATION; FATIGUE; HUMAN; METABOLISM; MUSCLE DISEASE; NEOPLASM; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADRENAL CORTEX HORMONES; ANOREXIA; FATIGUE; HUMANS; MUSCULAR DISEASES; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84928107182     PISSN: 17514258     EISSN: 17514266     Source Type: Journal    
DOI: 10.1097/SPC.0000000000000093     Document Type: Review

References (54)

1. Teunissen SCCM, Wesker W, Kruitwagen C, et al. Symptom prevalence in patients with incurable cancer: A systematic review. J Pain Symptom Manage 2007; 34:94-104.
2. Butt Z, Wagner LI, Beaumont JL, et al. Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage 2008; 35:20-30.
3. Yennurajalingam S, Urbauer DL, Casper KLB, et al. Impact of a palliative care consultation team on cancer-related symptoms in advanced cancer patients referred to an outpatient supportive care clinic. J Pain Symptom Manage 2011; 41:49-56.
4. de Raaf PJ, de Klerk C, Timman R, et al. Differences in fatigue experiences among patients with advanced cancer, cancer survivors, and the general population. J Pain Symptom Manage 2012; 44:823-830.
5. Bower JE, Lamkin DM. Inflammation and cancer-related fatigue: Mechanisms, contributing factors, and treatment implications. Brain Behav Immun 2013; 30 (Suppl 0):S48-S57.
6. Dantzer R, O'Connor JC, Freund GG, et al. From inflammation to sickness and depression: When the immune system subjugates the brain. Nat Rev Neurosci 2008; 9:46-56.
7. Grace PM, Hutchinson MR, Maier SF, Watkins LR. Pathological pain and the neuroimmune interface. Nat Rev Immunol 2014; 14:217-231.
8. Hains LE, Loram LC, Weiseler JL, et al. Pain intensity and duration can be enhanced by prior challenge: Initial evidence suggestive of a role of microglial priming. J Pain 2010; 11:1004-1014.
9. Cheung YT, Lim SR, Ho HK, Chan A. Cytokines as mediators of chemotherapy- Associated cognitive changes: current evidence, limitations and directions for future research. PLoS One 2013; 8:e81234.
10. Janelsins M, Mustian K, Palesh O, et al. Differential expression of cytokines in breast cancer patients receiving different chemotherapies: Implications for cognitive impairment research. Support Care Cancer 2012; 20:831- 839.
11. Miller AH, Maletic V, Raison CL. Inflammation and its discontents: The role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009; 65:732-741.
12. Raison CL, Miller AH. Is depression an inflammatory disorder? Curr Psychiatry Rep 2011; 13:467-475.
13. Barsevick A, Frost M, Zwinderman A, et al. I'm so tired: Biological and genetic mechanisms of cancer-related fatigue. Qual Life Res 2010; 19:1419- 1427.
14. Gupta SC, Kim JH, Kannappan R, et al. Role of nuclear factor-kB-mediated inflammatory pathways in cancer-related symptoms and their regulation by nutritional agents. Exp Biol Med (Maywood) 2011; 236:658-671.
15. Liu L, Mills PJ, Rissling M, et al. Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy. Brain Behav Immun 2012; 26:706-713.
16. Matsuo N, Morita T, Iwase S. Physician-reported corticosteroid therapy practices in certified palliative care units in Japan: A nationwide survey. J Palliat Med 2012; 14:840-845.
17. Lundström SH, Fürst CJ. The use of corticosteroids in Swedish palliative care. Acta Oncol 2006; 45:430-437.
18. Shih A, Jackson KC. Role of Corticosteroids in Palliative Care. J Pain Palliat Care Pharmacother 2007; 21:69-76.
19. Denton A, Shaw J. Corticosteroid prescribing in palliative care settings: A retrospective analysis in New Zealand. BMC Palliat Care 2014; 13:7.
20. Schimmer BP, Funder JW. Chapter 42. ACTH, adrenal steroids, and pharmacology of the adrenal cortex. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 12th ed New York: McGraw-Hill; 2011.
21. Bruera E, Moyano JR, Sala R, et al. Dexamethasone in addition to metoclopramide for chronic nausea in patients with advanced cancer: A randomized controlled trial. J Pain Symptom Manage 2004; 28:381-388.
22. Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999; 17:3299-3306.
23. Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. The Methylprednisolone Female Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989; 25:1823- 1829.
24. Della Cuna GR, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients: A placebocontrolled, multicenter study. The Methylprednisolone Preterminal Cancer Study Group. Eur J Cancer Clin Oncol 1989; 25:1817-1821.
25. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974; 33:1607- 1609.
26. Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al. Reduction of cancerrelated fatigue with dexamethasone: A double-blind, randomized, placebocontrolled trial in patients with advanced cancer. J Clin Oncol 2013; 31:3076-3082.
27. Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. Cancer Treat Rep 1985; 69:751-754.
28. Willox JC, Corr J, Shaw J, et al. Prednisolone as an appetite stimulant in patients with cancer. Br Med J (Clin Res Ed) 1984; 288:27.
29. Ioannidis JPA, Hesketh PJ, Lau J. Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: A meta-analysis of randomized evidence. J Clin Oncol 2000; 18:3409-3422.
30. Bower JE, Ganz PA, Dickerson SS, et al. Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 2005; 30:92- 100.
31. Bower JE, Ganz PA, Aziz N, et al. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav Immun 2007; 21:251-258.
32. Frank MG, Hershman SA, Weber MD, et al. Chronic exposure to exogenous glucocorticoids primes microglia to pro-inflammatory stimuli and induces NLRP3 mRNA in the hippocampus. Psychoneuroendocrinology 2014; 40:191-200.
33. McEwen BS, Biron CA, Brunson KW, et al. The role of adrenocorticoids as modulators of immune function in health and disease: neural, endocrine and immune interactions. Brain Res Brain Res Rev 1997; 23:79-133.
34. Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids: new mechanisms for old drugs. N Engl J Med 2005; 353:1711-1723.
35. Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: Benefits and pitfalls. Expert Rev Clin Pharmacol 2011; 4:233-242.
36. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502-1512.
37. Scholz J, Woolf CJ. The neuropathic pain triad: neurons, immune cells and glia. Nat Neurosci 2007; 10:1361-1368.
38. McEwen BS, Kalia M. The role of corticosteroids and stress in chronic pain conditions. Metabolism 2010; 59 (Suppl 1):S9-S15.
39. Mercadante SL, Berchovich M, Casuccio A, et al. A prospective randomized study of corticosteroids as adjuvant drugs to opioids in advanced cancer patients. Am J Hosp Palliat Care 2007; 24:13-19.
40. Paulsen Ø, Klepstad P, Rosland JH, et al. Efficacy of methylprednisolone on pain, fatigue, and appetite loss in patients with advanced cancer using opioids: A randomized, placebo-controlled double-blind trial. J Clin Oncol 2014. [Epub ahead of print].
41. Vardy J, Chiew KS, Galica J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006; 94:1011-1015.
42. Schakman O, Kalista S, Barbé C, et al. Glucocorticoid-induced skeletal muscle atrophy. Int J Biochem Cell Biol 2013; 45:2163-2172.
43. Okishiro N, Tanimukai H, Tsuneto S, Ito N. Can 'steroid switching' improve steroid-induced psychosis in a patient with advanced cancer? J Palliat Med 2009; 12:487-490.
44. Kang JH, Hui D, Kim MJ, et al. Corticosteroid rotation to alleviate dexamethasone- induced hiccup: A case series at a single institution. J Pain Symptom Manage 2012; 43:625-630.
45. Lee G-W, Oh SY, Kang MH, et al. Treatment of dexamethasone-induced hiccup in chemotherapy patients by methylprednisolone rotation. Oncologist 2013; 18:1229-1234.
46. Hardy JR, Rees E, Ling J, et al. A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med 2001; 15:3-8.
47. Sturdza A, Millar B-A, Bana N, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer 2008; 16:1041-1048.
48. Batchelor TT, Taylor LP, Thaler HT, et al. Steroid myopathy in cancer patients. Neurology 1997; 48:1234-1238.
49. Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf 2007; 30:861-881.
50. Pereira RMR, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine 2011; 78:41-44.
51. Gupta A, Gupta Y. Glucocorticoid-induced myopathy: pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab 2013; 17:913-916.
52. LaPier TK. Glucocorticoid-induced muscle atrophy: The role of exercise in treatment and prevention. J Cardiopulm Rehabil 1997; 17:76-84.
53. Braith RW, Welsch MA, Mills RM, et al. Resistance exercise prevents glucocorticoid-induced myopathy in heart transplant recipients. Med Sci Sports Exerc 1998; 30:483-489.
54. Yennurajalingam S, Willey JS, Palmer JL, et al. The role of thalidomide and placebo for the treatment of cancer-related anorexia-cachexia symptoms: results of a double-blind placebo-controlled randomized study. J Palliat Med 2012; 15:1059-1064.